ArticleCureus2025
Dysphagia During Pharyngeal and Esophageal Phase of Seronegative Immune-Mediated Necrotizing Myopathy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Seronegative Immune-Mediated Necrotizing Myopathy: An Overview for Optimal Clinical Management.Current rheumatology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-mediated necrotizing myopathy (IMNM) is a category of inflammatory muscle diseases that was identified as distinct from polymyositis. The majority of IMNM cases involve the presence of myositis-specific autoantibodies, specifically anti-signal recognition particle (anti-SRP) or anti-3-hydroxy-3-methylglutaryl-coA reductase (anti-HMGCR). However, some IMNM patients do not exhibit these antibodies, which is referred to as seronegative status. Swallowing difficulties are a common symptom in muscle diseases, including IMNM. However, there is a lack of research specifically investigating the swallowing disorder profile in patients with antibody-negative IMNM. We describe an 88-year-old Japanese woman case of seronegative IMNM with dysphagia. She developed pain and muscle weakness in the right shoulder followed by muscle weakness in the bilateral shoulder muscles and lower limbs. One year after initial onset, head ptosis and dysphagia developed and she visited our hospital. Based on muscle biopsy and blood tests, she was diagnosed with IMNM. At age 90, she was admitted to our hospital for treatment and received immunotherapy including intravenous methylprednisolone, oral prednisolone, methotrexate and intravenous immunoglobulin therapy. A swallowing screening test immediately after admission revealed coughing during water drinking, but this improved with thickened fluids. The patient continued to experience choking during meals, prompting a videofluoroscopic swallowing study (VF). VF showed decreased clearance of food residue during the pharyngeal phase and retention and reflux during the esophageal phase. Despite immunotherapy, the patient did not experience any significant improvement in clinical symptoms, including limb strength or dysphagia. This case report highlights dysphagia in a seronegative IMNM patient, demonstrating food retention and reflux in the lower esophagus and decreased pharyngeal clearance on VF. This suggests potential esophageal smooth muscle damage due to an autoimmune mechanism. Further research on dysphagia in IMNM, particularly in the seronegative type, is crucial to understand the pathogenesis and develop effective treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.